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Background
IgE-associated allergic diseases represent a global health 
problem increasing in prevalence and severity. An epi-
demic of IgE-associated allergic diseases has occurred 
over the past decades globally [1, 2] and many factors 
driving this epidemic are not clear. The most common 
diseases (asthma, rhinitis and eczema) are linked, at least 
partly, to IgE immune response. These diseases are com-
plex multifactorial disorders, with both genetic and envi-
ronmental components. Reasons explaining the allergy 
epidemic are not clear. Many inhalants such as air pol-
lution and diesel exhaust particulates are associated with 
a modulation of the IgE response [3]. On the other hand, 
tobacco smoking has a minimal effect on the increased 
prevalence or severity of allergic rhinitis [4].
Any new inhaled compound should be considered a 
potential adjuvant of the IgE immune response or non-
allergic mechanisms leading to a boost in the allergy 
epidemic. E-cigarettes are largely used to replace con-
ventional cigarette smoking with the intention to reduce 
known risks for smokers’ health; however, many side 
effects may still be unknown. Here we focus on the ques-
tion of whether allergy may be theoretically associated 
with e-cigarette use.
E‑cigarette vaping
The behaviour of smoking is a cardinal sign of a com-
plex, biosocial compulsive disorder of the brain—a dis-
order induced by repeated exposure to nicotine [5]. As a 
result, the global tobacco epidemic claims nearly 6 mil-
lion lives annually, despite a near-universal appreciation 
of the catastrophic health consequences of continued 
use [6]. Ambivalence, or the continuation of maladap-
tive behaviours in the face of a rational desire to stop, is 
the hallmark of nicotine dependence, and is frequently 
resolved by adopting compromise positions, including 
the use of “light” or filtered cigarettes [7].
The electronic cigarette, or “e-cigarette”, is the latest 
addition to the list of available compromise products 
introduced to western markets by the industry. A wide 
variety of devices are available, with an array of design 
features and constituent components that significantly 
influence the pharmacologic/toxicologic profile of each 
device [8]. Though the devices vary greatly in technical 
specifications, they most commonly deliver a nicotine-
containing aerosol to the aeropharyngeal mucosa, and 
have been heavily marketed as healthier alternatives to 
tobacco smoking. In addition to varying amounts of nico-
tine, the aerosol also delivers propylene glycol and veg-
etable glycerin, humectants used as a stabilizing vehicle 
and to create the appearance of smoke plumes, and one 
or more flavourant additives to increase the appeal of the 
product [9].
Precisely because the consequences of conventional 
smoking are so serious, it has been easy for e-cigarette 
users [10], physicians [11], and at least one professional 
society [12] to explicitly judge these electronic nicotine 
delivery devices to be safer than cigarettes. In fact, e-cig-
arette aerosols do contain far lower concentrations of 
common cigarette carcinogens on average [13, 14]. How-
ever, what is true of the average is not true of the individ-
ual products [15]. Neither is it true that carcinogenesis is 
the sole hazard presented by the aerosol. A growing body 
of evidence suggests that e-cigarette aerosol constituents 
may have their own unique hazard profile, distinct from 
that expected from smoke. For example, a number of dis-
turbances in airway epithelial, endothelial, and inflam-
matory regulatory physiology have been identified, with 
uncertain implications on long term health [16, 17].
In high school students in South Korea, e-cigarette 
users have an increased association with asthma and are 
more likely to have had days absent from school due to 
severe asthma symptoms [18].
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Effects of e‑cigarettes on human host defence 
and bacterial virulence
E-cigarette vapor inhaled into human airways interacts 
with several types of cells, including epithelial and mac-
rophages. Exposure of human cells to e-cigarette vapor 
has been found to alter innate immune responses and 
inflammatory signaling [17, 19–22]. In this way, e-cig-
arette use may induce inflammatory lung diseases or 
increase susceptibility to invasive bacterial pathogens 
by effects on mammalian airway cells. Acute e-cigarette 
vapor inhalation has been found to alter airway physiol-
ogy: 5  min of e-cigarette use increased airways resist-
ance and lowered the fractional exhalation of nitric oxide 
(NO), both of which suggest activation of pathways 
known to be important in asthma [23].
Mammalian cells are not the only residents of human 
airways. Bacterial pathogens such as Staphylococcus 
aureus (S. aureus) commonly colonize the airways and 
are exposed to inhalants. E-cigarette exposure imposes 
stress on S. aureus, inducing changes in the surface 
charge, hydrophobicity, and biofilm formation. Nicotine 
alone had subtle effects, while both aerosolized propyl-
ene glycol and vegetable glycerin had dramatic effects 
on bacterial pathogenicity, independently or when used 
together. Changes induced by e-cigarette vapor improved 
the ability of S. aureus to adhere to and invade epithelial 
cells, and increased resistance to human antimicrobial 
peptides. When unflavored e-cigarette vapor exposed 
S. aureus were introduced into mouse lungs, increased 
virulence was found via increased bacteria within lung 
parenchyma and increased mortality [17, 21]. Thus, the 
use of e-cigarettes may increase the incidence and sever-
ity of bacterial lung infections by both direct effects on 
human cells of host defense as well as effects on bacterial 
cells. It is unknown whether flavorants will also have pro-
virulent effects on bacteria.
Staphylococcus sensitization and allergic diseases
Staphylococcus aureus is a frequent colonizer of the 
upper and lower airways and the skin. In the nose, it may 
form biofilms and resides intramucosally, and has been 
associated with different types of T helper cell reactions; 
recently, arguments for a role also in Th2 immune dis-
eases such as chronic rhinosinusitis and asthma accumu-
late [24]. S. aureus forms a rich immune proteome, with 
more than 1500 different proteins comprising virulence 
factors, enterotoxins including classical superantigens, 
and proteins with enzymatic properties. Whereas the 
classical enterotoxins may activate T cell populations 
unspecifically via the variable ß-chain of T cell recep-
tors, other recently discovered molecules such as ser-
ine protease-like proteins (spls) obviously elicit a strong 
Th2-biased immune response and act as allergens or 
super-allergens, as they induce IgE formation also to 
inert proteins [25]. Spl-specific memory T cells elaborate 
Th2 cytokines including IL-4, IL-5 and IL-13, whereas 
small amounts of IFN-γ, IL-6, TNF and IL-17 are pro-
duced. IL-4 and IL-13 drive the immunoglobulin class 
switch to IgE, and IL-5 orchestrates activation and sur-
vival of eosinophils. Both protein families, enterotoxins 
and spls, have been found in human airway mucosa, and 
elicit, when given intra-tracheal in mice, an allergic lung 
inflammation. A typical hallmark of Th2 reactions is the 
formation of IgE; in the presence of staphylococcal supe-
rantigens, a polyclonal IgE formation is regularly found 
including several IgE antibodies directed towards classi-
cal and ECG-locus enterotoxins (SE-IgEs); the latter are 
indicators of a manifest immune reaction to S. aureus 
products. SE-IgE was significantly associated with asthma 
in 3000 Europeans [26] and was shown to be linked to 
severe asthma, atopic or non-atopic, both in European 
[27] and Asian populations [28]. MeDALL (Mechanisms 
of the Development of Allergy) proposed that S. aureus 
sensitization was associated with a re-occurrence of foe-
tal Type 2 signalling leading to the onset of IgE and non-
IgE dependent diseases [29, 30].
From a hypothesis to public health strategies
The hypothesis that e-cigarette increases S. aureus colo-
nisation and then induces sensitization is important to 
consider since S. aureus colonisation is needed for the 
development of an IgE immune response that is often 
associated with a polyclonal IgE response, allergic symp-
toms of the upper and lower airways including allergic 
rhinitis, severe asthma and/or chronic rhinosinusitis with 
nasal polyposis.
Although currently there is no confirmation that e-cig-
arette smoking may induce allergic diseases, there is suf-
ficient background to seriously consider this hypothesis 
and to test it in appropriate cross-sectional and longi-
tudinal epidemiologic studies. If the effect on S. aureus 
colonisation is important in e-cigarette users, the proof-
of-concept should already be demonstrable, as e-ciga-
rettes were introduced to the international market in 
2007 and now are used by upwards of 10% of US, Euro-
pean and Asian populations [31]. One possible differenti-
ating feature of e-cigarette-induced allergy would be that 
users may be prone to develop polysensitization whereas 
people developing allergic sensitization in adulthood are 
more often monosensitized or oligosensitized [32].
The next important step will be the identification of 
e-cigarette components which may induce allergic mech-
anisms: propylene glycol, glycerine, nicotine, flavorants 
or toxins produced by the aerosolization process. Ani-
mal studies may help guide human studies by narrow-
ing the field of relevant e-cigarette components, defining 
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molecular pathways affected by e-cigarette vapor, and 
assessing duration and extent of exposure needed to con-
fer increased risk of allergic disease. Large human trials 
will then be needed to confirm findings with a sufficient 
power to discriminate between the different types of 
e-cigarettes.
The most difficult task will be to derive health pro-
motion strategies from this hypothesis. Proponents of 
e-cigarettes will indicate that allergy and asthma are 
trivial diseases by comparison to putative cancer preven-
tion [12, 31, 33]. Opponents to e-cigarettes will take the 
asthma example as a major adverse health consequence 
of e-cigarette vapor inhalation. In any case, removal of 
the IgE-promoting components will be needed.
In conclusion, it is urgent to confirm or refute this 
hypothesis using appropriate studies.
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